A global pharmacopoeial alert was initiated with the British, European, Indian, International, Japanese, Mexican, United States and other global pharmacopoeial partners in response to the COVID-19 pandemic. Pharmacopoeial alerts are a mechanism that enable rapid discussions between pharmacopoeias to respond to urgent public health needs. The goal of this alert is for pharmacopoeias to work together to support the global public health response to the pandemic including providing support for manufacturers, regulators, and stakeholders on medicines critical to the COVID-19 response. Many medicines currently undergoing investigation for the treatment of COVID-19 are repurposed existing medicines. Whilst investigations continue to find a treatment for COVID-19, in order for any medicine to be safe and effective it is vital that the medicine be of assured quality for its intended use. Pharmacopoeial monographs support the objective assessment of medicines quality through the provision of methods, acceptance criteria and supporting information. Through collaboration with the world pharmacopoeias, a list of COVID-19 investigated medicines mapped to available monographs in world pharmacopoeias is available here. In addition a number of world pharmacopoeias have acted to increase the accessibility of supportive pharmacopoeial texts by making these freely available via their websites, website addresses are included within the list.